Spyre Therapeutics (SYRE) Announces Positive Results for Phase 1 Study of SPY003

​Spyre Therapeutics, Inc. (NASDAQ:SYRE) is one of the Hottest Small Cap Stocks to Buy Now. On November 4, Spyre Therapeutics, Inc. (NASDAQ:SYRE) announced positive interim Phase 1 results for SPY003, which is its novel, half-life extended Anti-IL-23 antibody. The treatment is being tested for curing inflammatory bowel disease and rheumatic diseases.

​During the trial, SPY003 showed a half-life of approximately 85 days, supporting maintenance dosing of three or six months. Management noted that the trial was randomized, double-blind, and placebo-controlled with 59 healthy volunteers at various doses. In addition, the drug also demonstrated a favourable safety profile, with no serious adverse events.

​On the same day, Julian Harrison of BTIG maintained Spyre Therapeutics, Inc. (NASDAQ:SYRE) with a Buy rating and a $70 price target. He noted that the extended half-life supports less frequent dosing, which is a critical advancement for SPY003 as a valuable component in combination therapies.

​Moreover, Harrison also mentioned the company’s unique ability to combine multiple monoclonal antibodies into a single treatment. In terms of finances, the analyst noted the company to be well-positioned with a substantial cash runway to fund operations till the second half of 2028.

​Spyre Therapeutics, Inc. (NASDAQ:SYRE) is a clinical-stage biotechnology company that develops antibody-based therapies for inflammatory bowel disease and other immune-related conditions.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.